Classification of and cytoreductive surgery for low-grade appendiceal mucinous neoplasms
British journal of surgery2012Vol. 99(7), pp. 987–992
Citations Over TimeTop 10% of 2012 papers
James R. McDonald, Sarah O’Dwyer, Shantanu Rout, Bipasha Chakrabarty, Kanwal A. Sikand, Paul Fulford, Malcolm Wilson, Andrew G. Renehan
Abstract
This study identified two LAMN subtypes. Type II lesions have pathological features of increased risk for dissemination and should be considered for risk-reducing cytoreductive surgery.
Related Papers
- → Morbidity, mortality and long-term survival in patients undergoing extended cytoreductive surgery with hyperthermic intraperitoneal chemotherapy(2012)
- → Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases in patients with colorectal cancer(2021)
- → 02 / Postoperative outcomes of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC)(2018)
- → Treatment and Survival Outcomes of Patients with Colorectal Peritoneal Metastases deemed Ineligible for Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)(2023)
- → Health-related quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is not different than cytoreductive surgery alone in primary ovarian cancer patients (009)(2023)